Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Elution and Regeneration of Protein A Column – V 2.0

Posted on By


Biosimilars: SOP for Elution and Regeneration of Protein A Column – V 2.0


Standard Operating Procedure for Elution and Regeneration of Protein A Column in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/156/2025
Supersedes SOP/BS/156/2022
Page No. Page 1 of 10
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the procedure for elution of bound monoclonal antibodies from Protein A affinity chromatography columns and subsequent regeneration of the column for reuse in biosimilar downstream processing.

2. Scope

This SOP is applicable to all Protein A columns used in the purification of monoclonal antibodies (mAbs) in biosimilar manufacturing across single-use or reusable chromatography systems.

3. Responsibilities

  • Production: Execute elution and regeneration procedures and monitor critical parameters.
  • QA: Verify and review elution recovery logs and resin regeneration data.
  • Engineering: Maintain and calibrate chromatography skids and monitor pressure profiles.

4. Accountability

The Head of Downstream Processing is accountable for ensuring successful product recovery and column reuse under validated and GMP-compliant conditions.

5. Procedure

5.1 Elution of Monoclonal Antibody

  1. Ensure equilibration and product loading are completed as per SOP/BS/155/2025.
  2. Prepare Elution Buffer (e.g., 0.1 M Glycine-HCl, pH 2.8–3.0).
  3. Connect the elution buffer line to the chromatography skid.
  4. Set the elution parameters:
    • Flow rate: 80–100 cm/hr
    • Volume: 3–5 column volumes (CV) or as validated
  5. Monitor UV at 280 nm. Start elution collection when UV absorbance exceeds 0.05 AU.
  6. Collect elution peak in pre-labeled sterile bags or bottles.
  7. Neutralize pooled elution fractions immediately using neutralization buffer (e.g., 1 M Tris-HCl, pH 8.0).
  8. Record the elution profile in Annexure-1: Elution Log Sheet and attach chromatogram printouts.

5.2 Post-Elution Wash

  1. Flush column with equilibration buffer until baseline UV is restored.
  2. This step removes loosely bound contaminants before regeneration.

5.3 Column Regeneration

  1. Prepare Regeneration Buffer (e.g., 0.1–0.5 M NaOH).
  2. Pass regeneration buffer at 100–150 cm/hr for 3–5 CV or for 20 minutes, whichever is longer.
  3. Allow static contact (soaking) for 15–30 minutes if specified in the resin manufacturer’s protocol.
  4. Rinse with WFI or storage buffer until pH stabilizes at 6.8–7.2.
  5. Record resin contact time and buffer volumes in Annexure-2: Regeneration Record.

5.4 Resin Storage (Reusable Columns)

  1. Store resin in appropriate storage solution (e.g., 20% ethanol) at 2–8°C if not reused immediately.
  2. Label storage status clearly on column tag and log storage start time.

5.5 Disposal (Single-Use Columns)

  1. Disconnect and discard single-use columns per biohazard disposal SOPs.
  2. Document lot traceability in Annexure-3: Column Usage and Disposal Log.

6. Abbreviations

  • mAb: Monoclonal Antibody
  • CV: Column Volume
  • NaOH: Sodium Hydroxide
  • WFI: Water for Injection

7. Documents

  1. Elution Log Sheet – Annexure-1
  2. Regeneration Record – Annexure-2
  3. Column Usage and Disposal Log – Annexure-3

8. References

  • WHO TRS 999 – Guidelines on Biotherapeutic Products
  • ICH Q8 – Pharmaceutical Development
  • OEM Resin Manual – Cytiva MabSelect, Repligen Amsphere

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Elution Log Sheet

Date Batch No. Elution Buffer Start Time End Time Volume Collected Operator
04/05/2025 BS-DP-084 Gly-HCl, pH 3.0 11:00 11:45 2.2 L Ajay Verma

Annexure-2: Regeneration Record

Date Column ID NaOH Conc. Contact Time Rinse Volume Final pH Performed By
04/05/2025 PA-01 0.5 M 20 min 8 L 7.1 Sunita Reddy

Annexure-3: Column Usage and Disposal Log

Column ID Used In Batch No. of Cycles Storage/Disposal Action Date Handled By
PA-SU-202 BS-DP-084 1 Disposed 04/05/2025 QA Officer

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Updated resin storage and disposal steps for single-use columns Compliance update
See also  Biosimilars: SOP for Harmonizing MCB/WCB Data with QA System - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Audit Gap: Non-Aligned SOP Versions Across QA, Validation, and Production
Next Post: Analytical Method Development: SOP for Validation Report Preparation and Review – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version